Adenosine receptors as therapeutic targets for the treatment of myocardial infarction and its complications. Part I. Myocardial infarction

1. Sanchis -Gomar F, Perez -Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016;4(13):256.10.21037/atm.2016.06.33Search in Google Scholar

2. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocar-dial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454-71.10.1016/j.jacc.2015.02.032Search in Google Scholar

3. Headrick JP, Ashton KJ, Rose’meyer RB, Peart JN. Cardiovascular adeno-sine receptors: expression, actions and interactions. Pharmacol Ther 2013;140(1):92-111.10.1016/j.pharmthera.2013.06.002Search in Google Scholar

4. Burnstock G, Pelleg A. Cardiac purinergic signalling in health and disease. Purinergic Signal 2015;11(1):1-46.10.1007/s11302-014-9436-1Search in Google Scholar

5. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.Search in Google Scholar

6. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/Reperfusion. Compr Physiol 2016;7(1):113-70.10.1002/cphy.c160006Search in Google Scholar

7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74(5):1124-36.10.1161/01.CIR.74.5.1124Search in Google Scholar

8. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007;116(2):173-91.10.1016/j.pharmthera.2007.06.005Search in Google Scholar

9. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285(2):H579-88.10.1152/ajpheart.01064.2002Search in Google Scholar

10. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre -, post-, and remote conditioning. Circ Res 2015;116(4):674-99.10.1161/CIRCRESAHA.116.305348Search in Google Scholar

11. Ely SW, Mentzer RM Jr, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 1985;90(4):549-56.10.1016/S0022-5223(19)38568-XSearch in Google Scholar

12. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A₁ adenosine receptors in rabbit heart. Circulation 1991;84(1):350-6.10.1161/01.CIR.84.1.350Search in Google Scholar

13. Schlack W, Schäfer M, Uebing A, Schäfer S, Borchard U, Thämer V. Aden-osine A₂-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 1993;22(1):89-96.10.1097/00005344-199307000-00015Search in Google Scholar

14. Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A₃ receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28(7):1057-61.10.1093/cvr/28.7.1057Search in Google Scholar

15. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A₁ -selective adenosine analogues protects the heart against infarction. Circulation 1992;85(2):659-65.10.1161/01.CIR.85.2.659Search in Google Scholar

16. Louttit JB, Hunt AA, Maxwell MP, Drew GM. The time course of cardio-protection induced by GR79236, a selective adenosine A₁ -receptor agonist, in myocardial ischaemia -reperfusion injury in the pig. J Cardiovasc Pharmacol 1999;33(2):285-91.10.1097/00005344-199902000-00016Search in Google Scholar

17. Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, et al. Selective activation of A₃ adenosine receptors with N₆ -(3 -iodobenzyl) adenosine -5’ -N -methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80(6):800-9.10.1161/01.RES.80.6.800Search in Google Scholar

18. Carr CS, Hill RJ, Masamune H, Kennedy SP, Knight DR, Tracey WR, et al. Evidence for a role for both the adenosine A₁ and A₃ receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 1997;36(1):52-9.10.1016/S0008-6363(97)00160-0Search in Google Scholar

19. Tracey WR, Magee W, Masamune H, Kennedy SP, Knight DR, Buchholz RA, et al. Selective adenosine A₃ receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33(2):410-5.10.1016/S0008-6363(96)00240-4Search in Google Scholar

20. Thourani VH, Nakamura M, Ronson RS, Jordan JE, Zhao ZQ, Levy JH, et al. Adenosine A₃ -receptor stimulation attenuates postischemic dysfunction through K_ATP channels. Am J Physiol 1999;277(1):H228-35.10.1152/ajpheart.1999.277.1.H22810409201Search in Google Scholar

21. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ. A₃ adenosine receptor agonist IB-MECA reduces myocardial ischemia -reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 2003;285(2):H607-13.10.1152/ajpheart.01001.2002386082212689858Search in Google Scholar

22. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Novel N⁶-substituted adenosine 5’ -N -methyluronamides with high selectivity for human adenosine A₃ receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 2003;285(6):H2780-7.10.1152/ajpheart.00411.200312919933Search in Google Scholar

23. Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, et al. Cl -IB--MECA [2 -chloro -N⁶ -(3 -iodobenzyl)adenosine -5’ -N -methylcarboxamid] reduces ischemia/reperfusion injury in mice by activating the A₃ adeno-sine receptor. J Pharmacol Exp Ther 2006;319(3):1200-10.10.1124/jpet.106.11135116985166Search in Google Scholar

24. Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, et al. The A₃ adenosine receptor agonist CP -532,903 [N⁶ -(2,5 -dichlorobenzyl) -3’- -aminoadenosine -5’ -N -methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP -sensitive potassium channel. J Pharmacol Exp Ther 2008;324(1):234-43.10.1124/jpet.107.127480Search in Google Scholar

25. Norton ED, Jackson EK, Turner MB, Virmani R, Forman MB. The effects of intravenous infusions of selective adenosine A₁ -receptor and A₂ -receptor agonists on myocardial reperfusion injury. Am Heart J 1992;123(2):332-8.10.1016/0002-8703(92)90643-ASearch in Google Scholar

26. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J. A₃ adenosine receptor activation attenuates neutrophil function and neutrophil -mediated reperfusion injury. Am J Physiol 1999;277(5):H1895-905.10.1152/ajpheart.1999.277.5.H189510564145Search in Google Scholar

27. Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA. A₃ adeno-sine receptor activation during reperfusion reduces infarct size through actions on bone marrow -derived cells. J Mol Cell Cardiol 2010;49(2):280-6.10.1016/j.yjmcc.2010.01.018288551620132822Search in Google Scholar

28. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten -Johansen J. Adenosine A₂ receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280(1):301-9.Search in Google Scholar

29. Lasley RD, Jahania MS, Mentzer RM Jr. Beneficial effects of adenosine A_2a agonist CGS -21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001;280(4):H1660-6.10.1152/ajpheart.2001.280.4.H166011247777Search in Google Scholar

30. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C -adenosine A_2b receptor cascade. Cardiovasc Res 2006;70(2):308-14.10.1016/j.cardiores.2006.02.01416545350Search in Google Scholar

31. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, et al. Myocardial infarct -sparing effect of adenosine A_2A receptor activation is due to its action on CD⁴⁺ T lymphocytes. Circulation 2006;114(19):2056-64.10.1161/CIRCULATIONAHA.106.64924417060376Search in Google Scholar

32. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, Linden J. Adenosine A_2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 2008;295(5):H1825-33.10.1152/ajpheart.495.2008261458918757481Search in Google Scholar

33. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, et al. Adenosine A_2A and A_2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009;47(5):684-90.10.1016/j.yjmcc.2009.08.009278274419695259Search in Google Scholar

34. Methner C, Schmidt K, Cohen MV, Downey JM, Krieg T. Both A_2a and A_2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 2010;299(4):H1262-4.10.1152/ajpheart.00181.2010295735120709859Search in Google Scholar

35. Urmaliya VB, Church JE, Coupar IM, Rose’Meyer RB, Pouton CW, White PJ. Cardioprotection induced by adenosine A₁ receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A_2A and A_2B receptors by endogenous adenosine. J Cardiovasc Pharmacol 2009;53(5):424-33.10.1097/FJC.0b013e3181a443e219333129Search in Google Scholar

36. Urmaliya VB, Pouton CW, Ledent C, Short JL, White PJ. Cooperative cardioprotection through adenosine A₁ and A_2A receptor agonism in ischemia -reperfused isolated mouse heart. J Cardiovasc Pharmacol 2010;56(4):379-88.10.1097/FJC.0b013e3181f03d0520930592Search in Google Scholar

37. Zhan E, McIntosh VJ, Lasley RD. Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor -mediated cardioprotection. Am J Physiol Heart Circ Physiol 2011;301(3):H1183-9.10.1152/ajpheart.00264.2011319108021743001Search in Google Scholar

38. Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Adenosine A₃ agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A₁ antagonist DPCPX. Am J Physiol Heart Circ Physiol 2001;281(2):H847-53.10.1152/ajpheart.2001.281.2.H84711454590Search in Google Scholar

39. Tian Y, Marshall M, French BA, Linden J, Yang Z. The infarct -sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A₃ and A₂A receptors. Basic Res Cardiol 2015;110(2):16.10.1007/s00395-015-0473-x25711314Search in Google Scholar

40. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, et al. Aden-osine A₁ agonist at reperfusion trial (AART): results of a three -center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14(6):607-14.10.1023/A:1007850527878Search in Google Scholar

41. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol 2016;13(4):193-209.10.1038/nrcardio.2016.5Search in Google Scholar

42. Wang J, Drake L, Sajjadi F, Firestein GS, Mullane KM, Bullough DA. Dual activation of adenosine A₁ and A₃ receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320(2-3):241-8.10.1016/S0014-2999(96)00901-6Search in Google Scholar

43. Hill RJ, Oleynek JJ, Magee W, Knight DR, Tracey WR. Relative importance of adenosine A₁ and A₃ receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J Mol Cell Cardiol 1998;30(3):579-85.10.1006/jmcc.1997.06219515033Search in Google Scholar

44. Armstrong S, Ganote CE. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A₃ receptor involvement. Cardiovasc Res 1994;28(7):1049-56.10.1093/cvr/28.7.10497525060Search in Google Scholar

45. Kuno A, Critz SD, Cui L, Solodushko V, Yang XM, Krahn T, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A_2b -dependent signaling during early reperfusion. J Mol Cell Cardiol 2007;43(3):262-71.10.1016/j.yjmcc.2007.05.016272954717632123Search in Google Scholar

46. Kuno A, Solenkova NV, Solodushko V, Dost T, Liu Y, Yang XM, et al. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A_2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008;295(3):H1288-95.10.1152/ajpheart.00209.2008254447918660452Search in Google Scholar

47. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6 -(3 -iodobenzyl) -adenosine-5’ -N -methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3β. J Pharmacol Exp Ther 2006;318(1): 124-31.10.1124/jpet.106.10147716611852Search in Google Scholar

48. Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, et al. A₁ or A₃ adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res 2001;88(5):520-8.10.1161/01.RES.88.5.52011249876Search in Google Scholar

49. Zhao TC, Kukreja RC. Late preconditioning elicited by activation of aden-osine A₃ receptor in heart: role of NF -κB, iNOS and mitochondrial K_ATP channel. J Mol Cell Cardiol 2002;34(3):263-77.10.1006/jmcc.2001.151011945020Search in Google Scholar

50. Dana A, Skarli M, Papakrivopoulou J, Yellon DM. Adenosine A₁ receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase - and protein kinase C -dependent mechanism. Circ Res 2000;86(9):989-97.10.1161/01.RES.86.9.98910807872Search in Google Scholar

51. Sarkar K, Cai Z, Gupta R, Parajuli N, Fox -Talbot K, Darshan MS, et al. Hypoxia -inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc Natl Acad Sci U S A 2012;109(26):10504-9.10.1073/pnas.1208314109338709022699503Search in Google Scholar

52. Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A₂B adenosine receptors. Trends Mol Med 2013;19(6):345-54.10.1016/j.molmed.2013.02.005367412623540714Search in Google Scholar

53. Reid EA, Kristo G, Yoshimura Y, Ballard -Croft C, Keith BJ, Mentzer RM Jr, et al. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling. Am J Physiol Heart Circ Physiol 2005;288(5):H2253-9.10.1152/ajpheart.01009.2004Search in Google Scholar

54. Koeppen M, Harter PN, Bonney S, Bonney M, Reithel S, Zachskorn C, et al. Adora2b signaling on bone marrow derived cells dampens myocardial ischemia -reperfusion injury. Anesthesiology 2012;116(6): 1245-57.10.1097/ALN.0b013e318255793cSearch in Google Scholar

55. Su Q, Nyi TS, Li L. Adenosine and verapamil for no -reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev 2015;(5):CD009503.10.1002/14651858.CD009503.pub3Search in Google Scholar

56. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24(2):116-47.10.1111/j.1527-3466.2006.00116.xSearch in Google Scholar

57. Kassimis G, Davlouros P, Patel N, De Maria G, Kallistratos MS, Kharbanda RK, et al. Adenosine as an adjunct therapy in ST elevation myocardial infarction patients: myth or truth? Cardiovasc Drugs Ther 2015;29(5): 481-93.Search in Google Scholar

58. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocar-dial infarction: results of a multicenter, randomized, placebo -controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34(6):1711-20.10.1016/S0735-1097(99)00418-0Search in Google Scholar

59. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Investigators. A randomized, double -blinded, placebo -controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD -II). J Am Coll Cardiol 2005;45(11):1775-80.10.1016/j.jacc.2005.02.06115936605Search in Google Scholar

60. Cohen MV, Downey JM. AMISTAD trials: possible reasons for lack of success. J Am Coll Cardiol 2006;47(6):1226-38.Search in Google Scholar

61. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, et al. Improvement in microvascular reflow and reduction of infarct size with adeno-sine in patients undergoing primary coronary stenting. Am J Cardiol 2005;96(10):1410-5.10.1016/j.amjcard.2005.06.09016275189Search in Google Scholar

62. Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2012;125(10):1713-9.Search in Google Scholar

63. Gao Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A PRISMA -compliant meta -analysis. Medicine (Baltimore) 2015;94(32):e1279.10.1097/MD.0000000000001279461669026266362Search in Google Scholar

64. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoro-nary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101(18):2154-9.10.1161/01.CIR.101.18.2154Search in Google Scholar

65. Grygier M, Araszkiewicz A, Lesiak M, Janus M, Kowal J, Skorupski W, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2011;107(8):1131-5.10.1016/j.amjcard.2010.12.01021310372Search in Google Scholar

66. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C, et al. High -dose intracoronary adenosine for myocardial salvage in patients with acute ST -segment elevation myocardial infarction. Eur Heart J 2011;32(7):867-77.10.1093/eurheartj/ehq49221196444Search in Google Scholar

67. Garcia -Dorado D, García -del -Blanco B, Otaegui I, Rodríguez -Palomares J, Pineda V, Gimeno F, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol 2014;177(3):935-41.10.1016/j.ijcard.2014.09.20325449504Search in Google Scholar

68. Singh M, Shah T, Khosla K, Singh P, Molnar J, Khosla S, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta -analysis of randomized controlled trials. Ther Adv Cardiovasc Dis 2012;6(3):101-14.10.1177/175394471244667022562999Search in Google Scholar

69. Polimeni A, De Rosa S, Sabatino J, Sorrentino S, Indolfi C. Impact of intra-coronary adenosine administration during primary PCI: A meta -analysis. Int J Cardiol 2016;203:1032-41.10.1016/j.ijcard.2015.11.08626630632Search in Google Scholar

70. Nazir SA, Khan JN, Mahmoud IZ, Greenwood JP, Blackman DJ, Kunadian V, et al. The REFLO -STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST -Elevation Myocardial Infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Southampton (UK): NIHR Journals Library; 2016. Efficacy and Mechanism Evaluation.10.3310/eme0309027929619Search in Google Scholar

71. Bulluck H, Sirker A, Loke YK, Garcia -Dorado D, Hausenloy DJ. Clinical benefit of adenosine as an adjunct to reperfusion in ST -elevation myocardial infarction patients: An updated meta -analysis of randomized controlled trials. Int J Cardiol 2016;202:228-37.10.1016/j.ijcard.2015.09.005466930526402450Search in Google Scholar

72. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017;38(11):774-84.Search in Google Scholar